Ionis Pharmaceuticals IncIONS
Price$44.65

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
Analyst Coverage
21analysts covering
Consensus: PositiveAs of 18 Aug 2026
FY Revenue (est.)
$920.8Mnext fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly246.1MTarget: 875000000 to 900000000
Tryngolza (olezarsen) Product Sales Quarterly27MTarget: 100000000 to 110000000
Dawnzera (donidalorsen) Product Sales Quarterly16MTarget: 110000000 to 120000000
Watch Items
  • FDA Supplemental New Drug Application (sNDA) for olezarsen in severe hypertriglyceridemia (sHTG)Trigger: PDUFA Action DateAction: Monitor FDA decision on or before June 30, 2026
  • FDA New Drug Application (NDA) for zilganersen in Alexander diseaseTrigger: PDUFA Action DateAction: Monitor FDA decision on or before September 22, 2026
  • FDA New Drug Application (NDA) for bepirovirsen in chronic hepatitis B (partnered with GSK)Trigger: PDUFA Action DateAction: Monitor FDA decision on or before October 26, 2026
Sign in / Sign up to read more

Research as of 2 Sep 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.